Cirrhosis Patients with ARDS Face an Uphill Battle

French researchers who looked at 816 ICU admissions involving patients with cirrhosis of the liver to see how the development of the acute respiratory distress syndrome (ARDS) during an ICU stay may impact their prognosis have uncovered new insights that may one day improve the outlook for these historically challenging patients.

Among the patients in the study, 621 required invasive mechanical ventilation, and 165 (26.6%) met the criteria for ARDS. ARDS typically developed within two days of ICU admission and was severe in half of the cases. While pneumonia was the leading risk factor, many of the patients developed ARDS secondary to cirrhosis complications, such as gastrointestinal bleeding with shock or sepsis.

The overall survival of these patients was especially troubling. The 28-day mortality rate was 75.2%, and the 90-day mortality rate topped 83%. These statistics remained consistent over time, even though severity scores saw a slight improvement between the 2007-2014 and 2015-2021 time frames covered by the study.

These findings run counter to what has happened in the overall ARDS population. Thanks to advances in ARDS management, mortality rates have steadily declined over the past couple of decades, leading the researchers to suggest that ARDS patients with cirrhosis have not benefited from those advances.

The authors went on to examine specific factors that may be increasing the risk of poor outcomes in these patients. According to their multivariable analysis, these three factors are associated with 28-day mortality in cirrhosis patients who develop ARDS in the ICU:

• Severity of liver disease, assessed by the Model for End-Stage Liver Disease (MELD) score.
• Severity of hypoxemia, reflected by the PaO₂/FiO₂ ratio at ARDS onset.
• Reason for ICU admission, with patients admitted primarily for acute respiratory failure having a significantly better prognosis than those who developed ARDS secondary to other complications.

Two clinically meaningful patient profiles were derived from these findings. Specifically, patients admitted for acute respiratory failure, often related to pneumonia, were less likely to die if they developed ARDS in the ICU than those who were admitted for non-respiratory complications and then went on to develop ARDS. Mortality rates for these groups were about 67% and about 84%, respectively.

The authors note that although causality cannot be inferred, clinicians may use this distinction to refine prognostic assessment and guide discussions about treatment intensity. For example, systematic screening for ARDS, which often goes unrecognized in patients with cirrhosis, could enable earlier treatment with lung-protective ventilation strategies.

They also believe their findings will spur additional research aimed at improving outcomes for these patients.

“ARDS affects more than one in four intubated patients with cirrhosis and remains associated with extremely high mortality,” they wrote. “Further research should focus on identifying phenotypes and management pathways associated with improved outcomes and on defining the role of early liver transplantation evaluation in this high-risk group.”

The study, considered the largest to date in this patient population, was published in the Journal of Intensive Medicine. 

Highlighted in RC Buzz April 27, 2026